Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Websiteanaptysbio.com
Twitter@AnaptysBio
CategoryBioTech
Phone858-362-6295
Employees
Founded2005

Offices

San Diego, USA
10835 Road To The Cure
Suite 100
San Diego, CA, 92121
USA

People

Co-Founder
Board of Directors
Board Member
Director
Executive Chair - San Diego

Funding

TOTAL $43M
FUNDING TOTAL $43M
Series A, 7/2006
Avalon Ventures
$2M
Series B, 11/2007
Novo A/S
Frazier Healthcare Ventures
Alloy Ventures
Avalon Ventures
Numenor Ventures
WS Investments
$33M
Partial Close, 10/2011
$8.02M
DEBT TOTAL $2.02M
Debt, 8/2013
$2.02M

Tags

AnaptysBio

AnaptysBio is a privately-held therapeutic antibody product company and the leader in the use of somatic hypermutation, or SHM, for antibody discovery and optimization. SHM is the body’s natural process for generating potent antibodies to fight disease. The Company’s SHM-Platform™ utilizes the key components of SHM and other techniques to generate antibodies for therapeutic applications through an iterative process of natural evolution and high-throughput selection – a process that has been referred to as “naturalizing” antibodies. This versatile platform can be used both to discover and optimize antibodies directed at specific disease targets and also affinity mature existing antibodies to improve their binding properties. In addition to providing a more powerful approach to antibody discovery and protein optimization, it addresses a growing void in the therapeutic antibody field due to a string of acquisitions and licensing deals that have reduced the availability of many technologies.

Recent Milestones

  • Check
    AnaptysBio — AnaptysBio Gets $17M in Licensing Deal (3/13/14)
    Posted 3/13/14 at 5:03am via socaltech.com
  • Dollar
    AnaptysBio received $2.02M in Debt funding. (8/30/13)
    Posted 10/14/13 at 11:10pm via sec.gov
  • Dollar
    AnaptysBio received $8.02M in Partial Close funding. (10/14/11)
    Posted 9/24/13 at 3:32am via sec.gov
  • Dollar
    AnaptysBio received $33M in Series B funding. (11/8/07)
    Posted 3/11/10 at 5:17am via anaptysbio.com
  • Dollar
    AnaptysBio received $2M in Series A funding. (7/31/06)
    Posted 4/29/10 at 12:38am
  • Check
    AnaptysBio added William Boyle as President & Chief Science Officer.
    Posted 11/6/13 at 8:36am

Videos

Screenshots

AnaptysBio screenshot
Above: AnaptysBio
Uploaded: 3/11/10

Sources

  1. EDGAR [edit]
  2. AnaptysBio raises over $33 million in Series B financing (anaptysbio.com) [edit]
  3. SEC (sec.gov) [edit]
  4. SEC (sec.gov) [edit]
  5. AnaptysBio Gets $17M in Licensing Deal (socaltech.com) [edit]
Edit This Page
Last Edited 3/13/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy